Abstract                                                                                                                                                                                                                                                                             Background: Glaucoma is a chronic, progressive optic neuropathy and a leading cause of irreversible blindness worldwide. Reduction of intraocular pressure (IOP) remains the only proven strategy to slow disease progression. Fixed-drug combinations are commonly used to enhance IOP control and improve treatment adherence. While Brimonidine + Timolol is an established combination, comparative data with newer combinations such as Ripasudil + Timolol, particularly in the Indian population, remain limited. Materials and Methods: This prospective, randomized, hospital-based interventional study was conducted in the Department of Ophthalmology at a tertiary care centre in North India. Ninety newly diagnosed patients with primary open-angle glaucoma or normal-tension glaucoma were randomly allocated into two equal groups. Group 1 received Brimonidine + Timolol, and Group 2 received Ripasudil + Timolol. Intraocular pressure was assessed at baseline, 1 hour, 1 week, and 4 weeks after advising drug for twice a day.. Safety and tolerability were evaluated during follow-up. Statistical analysis was performed using Student’s t-test and chi-square test, with p <0.05 considered statistically significant. Results: Baseline demographic characteristics, clinical profile, and ocular parameters were comparable between the two groups (p >0.05). Both fixed-drug combinations produced a significant reduction in intraocular pressure following initiation of therapy. Intraocular pressure reduction at 1 hour and 1 week was comparable between the two groups (p >0.05). At 4 weeks, Group 2 demonstrated a significantly greater reduction in intraocular pressure compared to Group 1 (p <0.001). Both treatment regimens were well tolerated, with mild and self-limiting adverse effects. Conclusion: Both Brimonidine + Timolol and Ripasudil + Timolol are effective and safe for short-term management of glaucoma. However, Ripasudil + Timolol demonstrated superior for short-term intraocular pressure control.